CVE-2012-2112

Description

Cross-site scripting (XSS) vulnerability in the Exception Handler in TYPO3 4.4.x before 4.4.15, 4.5.x before 4.5.15, 4.6.x before 4.6.8, and 4.7 allows remote attackers to inject arbitrary web script or HTML via exception messages.

Category

4.3
CVSS
Severity: Medium
CVSS 2.0 •
EPSS 0.50%
Vendor Advisory debian.org Vendor Advisory typo3.org
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
http://lists.typo3.org/pipermail/typo3-announce/2012/000241.html mailing list
https://exchange.xforce.ibmcloud.com/vulnerabilities/74920 vdb entry
http://www.securityfocus.com/bid/53047 vdb entry
http://lists.typo3.org/pipermail/typo3-announce/2012/000242.html mailing list
http://www.openwall.com/lists/oss-security/2012/04/17/5 mailing list
http://www.openwall.com/lists/oss-security/2012/04/18/1 mailing list
http://www.debian.org/security/2012/dsa-2455 vendor advisory
http://typo3.org/teams/security/security-bulletins/typo3-core/typo3-core-sa-2012-002/ vendor advisory

Frequently Asked Questions

What is the severity of CVE-2012-2112?
CVE-2012-2112 has been scored as a medium severity vulnerability.
How to fix CVE-2012-2112?
To fix CVE-2012-2112, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2012-2112 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2012-2112 is being actively exploited. According to its EPSS score, there is a ~1% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.